Related Experiment Video
Updated: Jun 19, 2026

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
In-vitro activity of ceftazidime, a beta-lactamase stable cephalosporin
1Division of Infectious Diseases, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
Abstract:
The in-vitro activity and beta-lactamase stability of ceftazidime were evaluated against 700 Gram-positive and Gram-negative bacteria. Ceftazidime was less active than penicillins or older cephalosporins against Staphylococcus spp. and Streptococcus spp., and it did not inhibit Streptococcusfaecalis. However, ceftazidime was as active as moxalactam and cefoperazone against Escherichia coli, Klebsiella and Proteus mirabilis with MICs less than 0.2 mg/l. Ceftazidime also inhibited Enterobacter, Citrobacter, Salmonella and Shigella at concentrations below 0.2 mg/l. Most Morganella, Pr. rettgeri, Pr. vulgaris and Pr. inconstans were inhibited at concentrations below 1 mg/l similar to concentrations for moxalactam, cefoperazone, and cefotaxime. Ceftazidime was the most active agent tested against Ps. aeruginosa, with a mean MIC of 1.6 mg/l. It inhibited carbenicillin, piperacillin, cefoperazone, cefsulodin resistant Pseudomonas.
Related Concept Videos
Inhibitors of Gram-positive Cell Wall Synthesis
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

